Ibex Investors’s Syndax Pharmaceuticals SNDX Stock Holding History

Ibex Investors’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-13,754	Closed	-$103K	–	71
2019 Q3	$103K	Buy	+13,754	New	+$125K	0.01%	55

Other funds holding SNDX

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ibex Investors's SNDX Position: Q4 2019 in Review

Ibex Investors sold out of Syndax Pharmaceuticals (SNDX) in Q4 2019, closing a stake of 13,754 shares — an estimated $103K sold.

Ibex Investors first reported a position in SNDX in Q3 2019 and held it in 1 quarter. The position peaked at $103K in Q3 2019. 72 funds tracked by Wall St. Rank hold SNDX as of Q4 2019.

Ibex Investors reported no remaining Syndax Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
Ibex Investors sold 13,754 Syndax Pharmaceuticals shares in Q4 2019, an estimated $103K.
Ibex Investors first reported a position in Syndax Pharmaceuticals in Q3 2019 and held it in 1 quarter.
Ibex Investors's Syndax Pharmaceuticals position peaked at $103K in Q3 2019.
72 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q4 2019.

Based on Ibex Investors's 13F filing for Q4 2019, filed 5 Feb 2020.